a stereoisomer of ATRA, was recently found to be a highaffinity ligand for RXR.26, 27 We have shown that 9 4 s RA is more potent than ATRA in inducing differentiation and inhibiting proliferation of acute myelogenous leukemia (AML) cell lines and fresh leukemic cells from patients, including those with APL and AML M2 French-AmericanBritish [FAB] classification."
Despite the wide clinical application of ATRA for the treatment of APL, its effects on bone marrow stroma are totally unknown. We report here the effects of ATRA and 9 4 s RA on cytokine production by human bone marrow stromal cells and stromal cell lines and on the expression and regulation of RAR-a and RXR-a mRNAs by stromal cells.
B
Blood, Vol 84, No 12 (December 15). 1994: pp 4107-4115 CSF) constitutively, enhanced mRNA levels of both cytokines in a dose-dependent manner. Both RAs also stimulated M-CSF production from primary cultures of human bone marrow stromal cells. Both retinoic acid receptor (FIAR)-a and retinoid X receptor (RXRI-a were expressed constitutively in KMlOl cells. ATRA did not affect the expression of either receptor, whereas 9-cis RA increased RXR-a mRNA expression in a dose-dependent manner, but did not affect levels of RAR-a mRNA. These findings may have important biologic implications for both the role of RAs in hernatopoiesis and the therapeutic effects of ATRA on the hematopoietic microenvironment in patients with acute promyelocytic leukemia (APL). 0 1994 b y The American Society of Hematology.
MATERIALS AND METHODS
Cells. K M l O l is a well-characterized functional bone marrow stromal cell line generated by transfecting 6-week-old human bone marrow stromal cell primary cultures with recombinant plasmid pSV3gpt DNA containing the coding sequence of the early region of simian virus 40 (SV-40).z9 K M l O l cells are fibroblastic in appearance and produce several cytokines constituti~ely.~~ The cells were maintained in a-minimal essential medium (a-MEM; GIBCO, Santa Clara, CA) with 10% fetal bovine serum (Cytosystems, New South Wales, Australia) and 1% penicillin and streptomycin (GIBCO), and passaged with 0.25% trypsin (GIBCO). All experiments were performed using cells in logarithmic growth phase.
Long-term bone marrow cultures (LTBMC) were established as described3' from normal human bone marrow cells obtained from bone marrow transplant donors with informed consent. Briefly, lightdensity bone marrow cells were isolated by density gradient centrifugation on Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ), and suspended in 75-cmz tissue culture flasks (Coming Glass Works, Coming, NY) at a final concentration of 1 X lo6 cells/mL. Cultures were maintained at 37°C in a humidified 5% CO, atmosphere with complete replacement of medium weekly and the removal, at each medium change, of all nonadherent cells. Cells were passaged twice with 0.25% trypsin (GIBCO) before use.
Chemicals. ATRA (Sigma Chemical CO, St Louis, MO) was dissolved in 100% ethanol at concentrations of lo-* m o m and stored at -20°C in the dark. The 9-cis RA was kindly provided by H.P. 
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m -. Boston, MA) was added for the last 4 hours of incubation. Cells were washed, treated with phosphate-buffered saline (PBS) containing 1% EDTA, harvested, precipitated in S% trichloroacetic acid (TCA), (30 mmol/L Na2HP04) at 4°C for I hour, filtered onto glass microfiber membranes (Whatman. Hillsboro, OR), and washed in 3% TCA (30 mmol/L Na2HP04). Samples were assayed by liquid scintillation counting.
RNA exrracrion and Northern andysis. Confluent stromal cells were harvested and total RNA was extracted by the method of Chomczynski and Sacchi." RNA samples (S to 20 pg) were electrophoresed and size-fractionated on 1.0% agarose gels (GIBCO BRL, Gaithersberg, MD) containing 17% formaldehyde and transferred to nylon membranes (Hybond N', Amersham, Arlington Heights, IL). cDNA probes for Northern analysis were labeled with ["PIdCTP by using a random primer DNA labeling kit (Takara Shuzo CO, LTD.
Tokyo, Japan). Hybridization with the labeled probe was carried out for 16 to 48 hours at 42°C in SO% formamide, 2 X SSC (1 X SSC = I .S mmol/L sodium citrate, pH 7.0). S X Denhardt's, 0.1 % SDS, 10% dextran sulfate (Pharmacia), and 1 0 0 mg/mL salmon sperm DNA (Sigma). Filters were washed to stringency of 0.1 X SSC at 65°C and exposed to Kodak XAR film (Eastman Kodak, Rochester, NY). Autoradiograms were exposed from 24 hours to 7 days and hybridization signals were quantitated by scanning densitometer (Advantec DM-303, Tokyo, Japan). DNA probes. cDNA probes for human M-CSF and human GM-CSF were the Xhol-EcoRI fragment (2.0 kb) from plasmid pXMZ2 and the EcoRI-EcoRI fragment (0.8 kb) from plasmid p91023(B),1' respectively. A human RAR-a cDNA (Kpnl-EcoRI; 1.9 kb) was purified from plasmid pSG12" and a human RXR-a cDNA probe (EcoRI-EcoRI; 1.9 kb) was purified from pSMR3-I . 24 The 8-actin probe was the EcoRI-BarnHI fragment (0.7 kb) from plasmid pHFbA-3'."
Assays f i r cyrokine concenrrarion. Concentrations of GM-CSF in culture supernatants were assayed by enzyme-linked immunosorbent assay (ELISA) (BIOTRAK, Amersham) according to the manufacturer's protocol. M-CSF concentrations were also measured by ELISA as follows: samples were spotted onto anti-M-CSFantibodycoated 96-well plates and after I hour, wells were washed with PBS, reacted with rabbit anti-M-CSF antibody (IgG), washed again and reacted with peroxidase-labeled goat antirabbit IgG antibody. Absorbance at 492 nm was measured by spectrophotometer, and M-CSF concentrations were calculated according to the standard concentration curve.
Flow cyrornerry. KM101 cells were treated with ATRA (IO" mol/L) and 9 4 s RA (IO" mol/L) for 24 hours, harvested by PBS containing 1% EDTA, incubated with horse anti-M-CSF antibody (generous gift from Green Cross CO, Osaka, Japan) at 4°C for 30 minutes, followed by fluorescein isothiocyanate (FITC) 
RESULTS
Effects of retinoids on cytokine production by KM101 cells. KMlOl cells produce M-CSF and GM-CSF constitutively as detected by ELISA. ATRA and 9-cis RA enhanced M-CSF and GM-CSF production in a dose-dependent manner, although 9-cis RA was more potent in inducing the enhancement (Fig IA and B) . To exclude the possibility that enhanced M-CSF and GM-CSF levels reflect increased cell proliferation stimulated by the RAs, "-thymidine incorporation and cell counts were measured in cells incubated with RAs for 2 days. 'H-thymidine incorporation increased slightly (1.4-fold maximum) at RA concentrations of IO-' mol& but cell counts were unchanged at any concentration of RAs tested (data not shown).
Previous studies have reported three different mRNAs of M-CSF that arise by alternative splicing.3'.'s.3' However, KMlOl cells expressed only 4.0-kb mRNA by Northern blotting analysis, and both ATRA and 9-cis RA enhanced M-CSF and GM-CSF mRNA expression in a dose-dependent manner (Fig IC and D) .
Time course analysis of M-CSF and GM-CSF mRNA expression after addition of ATRA or 9-cis RA showed induction of mRNA of both cytokines at 3 to 6 hours after addition of RAs, with a plateau or a slight decrease between 12 and 24 hours (Fig 2) . 
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the half-lives of these mRNAs (Fig 3) . The calculated halflives of M-CSF and GM-CSF mRNA were about 3 hours and 0.6 hours, respectively. To analyze cell surface expression of M-CSF, excluding the possibility of entrapment of M-CSF in the culture medium by the extracellular matrix (Fig 4D) . Effects of R A s on normal human bone marrow stromal cells. Unlike KMlOl cells, normal human bone marrow stroma is a heterogeneous mix that includes fibroblasts, endothelial cells, macrophages, adipocytes, and preadipo~y t e s .~~ Therefore, we examined the effects of RAs on primary cultures of normal human bone marrow stromal cells, LTBMC. Both ATRA and 9-cis RA induced M-CSF production by LTBMC in a dose-dependent manner (Fig 5A) . Again, 9-cis RA was slightly more potent than ATRA.
Northern blot analysis gave consistent results at the mRNA level (Fig 5B) . The enhancement of M-CSF production was comparable to that of TNF-a ( l 0 ng/mL) (Fig 5A and B) . We could not detect GM-CSF production either by ELISA or Northern blotting (data not shown).
Effects of RAs on RAR-a and RXR-(Y mRNA expression.
For 
M -CSF
To analyze the signalling pathway of both retinoids, the effects of ATRA and 9-cis RA on RAR-a and RXR-a mRNA expression by KM IO1 cells were examined by Northem blotting. RAR-a and RXR-a were expressed constitutively in untreated KMlOl cells; RAR-a mRNA expression was not affected by either retinoid at various concentrations (Fig 6A and B) , whereas RXR-a mRNA was induced by 9-cis RA (Fig 6D) but not by ATRA (Fig 6C) in a dosedependent manner.
DISCUSSION
The present study demonstrates that ATRA and 9-cis RA stimulate M-CSF and GM-CSF production by human bone marrow stromal cells. These stimulatory effects on cytokine production were comparable to that of TNF-a (Fig 5A and  B) . Thus RAs, as well as TNF-a, can act as stimuli for cytokine production by stromal cells.
Although RA stimulated both M-CSF and GM-CSF production in KMlOl cells, human bone marrow stromal cell primary culture produced only M-CSF in response to RAs. The differences are probably due to the cellular heterogeneity of bone marrow stroma. Possibly, particular cell types that produce only M-CSF in response to RAs predominate in the population during culture in the flask. Alternatively, cytokine gene expression and responses to mitogenic stimuli may be aberrant in the virally transformed KMlOl cells, as compared with that of normal bone marrow stromal cells. In fact, KMlOl cells produce relatively high levels of M-CSF, G-CSF, and GM-CSF constitutively, whereas LTBMCs produce no measurable levels of these cytokines without stimulation. The 9 4 s RA was a more potent stimulator than ATRA in all experiments, consistent with previous studies describing the greater relative potency of 9-cis RA compared with ATRA in inducing differentiation of HL-60 cells and leukemic cells from AML patients." The 9-cis RA binds and activates both RAR and RXR efficiently, whereas ATRA binds and activates only RAR. The greater potency of 9-cis RA might rest in its ability to act, not only through RAR, but also by forming heterodimers of RAR and RXR'"" or RXR-RXR homodimers.'"
We previously demonstrated that 9-cis RA downregulates RXR-a expression in a dose-dependent manner during 9 4 s RA-induced differentiation of HL-60 cells,4' suggesting a role for RXR genes in cellular differentiation. In the present study, we find a dose-dependent upregulation of RXR-a expression by 9-cis RA in conjunction with enhancement of M-CSF and GM-CSF production. It remains unclear whether RXR-a induction is the cause or the result of the enhanced cytokine production. However, if the induction of RXR-a has some role in enhancement of cytokine production, RXRdependent pathways through RAR-RXR or RXR-RXR must be critical in the action of 9-cis RA. ATRA is currently the first therapeutic choice in the treatment of APL patients, in whom it is used as a differentiationinducing agent. Under ATRA therapy, serum ATRA concentrations can readily reach mol/L;' which is sufficient to stimulate cytokine production in stromal cells, as shown in this study and may modulate proliferation and differentiation of leukemic cells. Indeed, the hyperleukocytosis that occurs from 1 to 3 weeks after initiation of ATRA therapyl4lX is thought to reflect the elongation of life span or the rapid proliferation of APL cells along with differentiation. Although the factors that affect the life span and proliferation of APL cells have not been identified, our study raises the possibility that the stimulatory effects on cytokine production by RA might be involved. For example, RA might stimulate stromal cells in patients with APL to produce M-CSF, which in turn, might directly modulate proliferative state of APL cells undergoing differentiation, or stimulate monocytes to induce production of cytokines that enhance proliferation and differentiation of APL cells. Although M-CSF does not often promote growth of AML cells in vitro as compared with G-CSF,h2.4s it does stimulate G-CSF production by monocytes in vitro.& We detected no GM-CSF production in the LTBMC system, but undetectable amounts of GM-CSF produced by bone marrow stromal cells might be concentrated in the surrounding mi~roenvironment~~ and might act preferentially on APL cells attached to the stroma, promoting their growth and differentiation. Clarification of the precise mechanism of hyperleukocytosis awaits further study.
Our demonstration here that RAs (ATRA and 9 4 s RA) can stimulate M-CSF and GM-CSF production in human bone marrow stromal cells may have important implications in proliferation and differentiation of leukemic cells in patients with APL undergoing ATRA therapy.
